These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25199827)

  • 1. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
    Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
    Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic instability establishes dependencies on acquired gene regulatory networks: A novel role of p62 in myeloid malignancies with del(5q).
    Fang J; Starczynowski DT
    Mol Cell Oncol; 2015; 2(4):e1014219. PubMed ID: 27308507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
    Varney ME; Niederkorn M; Konno H; Matsumura T; Gohda J; Yoshida N; Akiyama T; Christie S; Fang J; Miller D; Jerez A; Karsan A; Maciejewski JP; Meetei RA; Inoue J; Starczynowski DT
    J Exp Med; 2015 Oct; 212(11):1967-85. PubMed ID: 26458771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic deletions in AML and MDS.
    Ebert BL
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
    Su YL; Wang X; Mann M; Adamus TP; Wang D; Moreira DF; Zhang Z; Ouyang C; He X; Zhang B; Swiderski PM; Forman SJ; Baltimore D; Li L; Marcucci G; Boldin MP; Kortylewski M
    Blood; 2020 Jan; 135(3):167-180. PubMed ID: 31805184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.
    Starczynowski DT; Kuchenbauer F; Argiropoulos B; Sung S; Morin R; Muranyi A; Hirst M; Hogge D; Marra M; Wells RA; Buckstein R; Lam W; Humphries RK; Karsan A
    Nat Med; 2010 Jan; 16(1):49-58. PubMed ID: 19898489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF-κB pathway.
    He L; Wang Z; Zhou R; Xiong W; Yang Y; Song N; Qian J
    Biomed Pharmacother; 2021 Jan; 133():110993. PubMed ID: 33220608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.
    Gañán-Gómez I; Wei Y; Yang H; Pierce S; Bueso-Ramos C; Calin G; Boyano-Adánez Mdel C; García-Manero G
    PLoS One; 2014; 9(4):e93404. PubMed ID: 24690917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome.
    Varney ME; Choi K; Bolanos L; Christie S; Fang J; Grimes HL; Maciejewski JP; Inoue JI; Starczynowski DT
    Leukemia; 2017 Feb; 31(2):491-495. PubMed ID: 27733775
    [No Abstract]   [Full Text] [Related]  

  • 13. MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulating TLR4/TRAF6/NF-κB pathway.
    He X; Zheng Y; Liu S; Shi S; Liu Y; He Y; Zhang C; Zhou X
    J Cell Physiol; 2018 Mar; 233(3):2476-2488. PubMed ID: 28771774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of microRNA-146a on the proliferation and apoptosis of human osteoarthritis chondrocytes by targeting
    Zhong JH; Li J; Liu CF; Liu N; Bian RX; Zhao SM; Yan SY; Zhang YB
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28314786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
    Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
    Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
    Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
    Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
    Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
    Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
    [No Abstract]   [Full Text] [Related]  

  • 20. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.